发明名称 |
SHORT-FORM HUMAN MD-2 AS A NEGATIVE REGULATOR OF TOLL-LIKE RECEPTOR 4 SIGNALING |
摘要 |
The present invention is based on a novel, alternatively spliced human isoform of MD-2 (MD-2s). In addition, the present invention relates to modified MD-2 proteins, wherein one or more tyrosine residues have been mutated to phenylalanine. In various embodiments, the invention relates to methods and kits for preventing, reducing the likelihood of developing and/or treating various conditions using MD-2s. The invention also describes methods of determining the risk of a subject to various conditions. |
申请公布号 |
US2015218246(A1) |
申请公布日期 |
2015.08.06 |
申请号 |
US201514639782 |
申请日期 |
2015.03.05 |
申请人 |
Cedars-Sinai Medical Center |
发明人 |
Arditi Moshe;Gray Pearl S. |
分类号 |
C07K14/705 |
主分类号 |
C07K14/705 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of inhibiting toll-like receptor 4 signaling (“TLR4”), inhibiting lipopolysaccharide (“LPS”) signaling, treating a condition mediated by TLR4 signaling, or reducing a likelihood of developing a condition mediated by TLR4 signaling in a subject in need thereof, comprising:
providing a purified polypeptide comprising an amino acid sequence that is at least 80% identical to SEQ ID NO:1 or SEQ ID NO:2; and administering the polypeptide to the subject to inhibit TLR4 signaling, inhibit LPS signaling, treat the condition mediated by TLR4 signaling, or reduce the likelihood of developing the condition mediated by TLR4 signaling. |
地址 |
Los Angeles CA US |